- Home
- PEBK vs SAVA Comparison
PEBK vs SAVA Comparison
Compare PEBK & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBK
- SAVA
- Stock Information
- Founded
- PEBK 1912
- SAVA 1998
- Country
- PEBK United States
- SAVA United States
- Employees
- PEBK N/A
- SAVA N/A
- Industry
- PEBK Major Banks
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- PEBK Finance
- SAVA Health Care
- Exchange
- PEBK Nasdaq
- SAVA Nasdaq
- Market Cap
- PEBK 169.6M
- SAVA 137.2M
- IPO Year
- PEBK N/A
- SAVA N/A
- Fundamental
- Price
- PEBK $25.72
- SAVA $1.44
- Analyst Decision
- PEBK
- SAVA Buy
- Analyst Count
- PEBK 0
- SAVA 3
- Target Price
- PEBK N/A
- SAVA $54.50
- AVG Volume (30 Days)
- PEBK 8.9K
- SAVA 2.2M
- Earning Date
- PEBK 04-29-2025
- SAVA 05-09-2025
- Dividend Yield
- PEBK 3.53%
- SAVA N/A
- EPS Growth
- PEBK 7.58
- SAVA N/A
- EPS
- PEBK 2.98
- SAVA N/A
- Revenue
- PEBK $82,079,000.00
- SAVA N/A
- Revenue This Year
- PEBK N/A
- SAVA N/A
- Revenue Next Year
- PEBK N/A
- SAVA N/A
- P/E Ratio
- PEBK $8.63
- SAVA N/A
- Revenue Growth
- PEBK 7.90
- SAVA N/A
- 52 Week Low
- PEBK $23.74
- SAVA $1.15
- 52 Week High
- PEBK $33.31
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- PEBK 44.11
- SAVA 37.19
- Support Level
- PEBK $25.10
- SAVA $1.17
- Resistance Level
- PEBK $27.10
- SAVA $1.46
- Average True Range (ATR)
- PEBK 1.41
- SAVA 0.13
- MACD
- PEBK -0.03
- SAVA 0.04
- Stochastic Oscillator
- PEBK 41.95
- SAVA 60.42
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh, and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.